HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Provided By GlobeNewswire
Last update: Aug 9, 2024
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024
The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults
Read more at globenewswire.com
